Real-world experiences of folic acid supplementation (5 versus 30 mg/week) with methotrexate in rheumatoid arthritis patients: a comparison study
Submitted: 20 February 2016
Accepted: 1 August 2016
Published: 9 September 2016
Accepted: 1 August 2016
Abstract Views: 2152
PDF: 1313
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- E. Quattrocchi, M. Feldmann, Recombinant adenovirus-mediated gene transfer suppresses experimental arthritis , Reumatismo: Vol. 53 No. 1 (2001)
- C. Botsios, P. Sfriso, A. Furlan, P. Ostuni, M. Biscaro, U. Fiocco, S. Todesco, L. Punzi, Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis , Reumatismo: Vol. 59 No. 1 (2007)
- M. Parodi, L. Bensi, T. Maio, G.S. Mela, M.A. Cimmino, Comorbidities in rheumatoid arthritis: analysis of hospital discharge records , Reumatismo: Vol. 57 No. 3 (2005)
- C. Montecucco, Outcome predictors in rheumatoid arthritis , Reumatismo: Vol. 56 No. s1 (2004)
- N. Şen, R. Mercan, G. Geçmez, B. Ediz, O. Volkan, S. Yilmaz-Oner, M.E. Tezcan, Psoriasis and family history of psoriasis may not affect disease severity of rheumatoid arthritis , Reumatismo: Vol. 73 No. 4 (2021)
- G. De Marco, V. Gerloni, I. Pontikaki, A. Lurati, B. Teruzzi, A. Salmaso, E. Valcamonica, M. Gattinara, F. Fantini, Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy , Reumatismo: Vol. 59 No. 1 (2007)
- M.L. Ciompi, C. Amoresano, P. Balzarini, L.M. Bazzichi, M. Broggini, L. Buratti, F. Calcagnile, A. Ciocci, S. Ferri, C. Fichera, M. Fumagalli, M. Muratore, F. Nitti, G. Peruz, G. Romagnoni, Sodium-gold thyosolphatum therapy: an open, viewed, multicenter trial in rheumatoid arthritis patients followed for two years , Reumatismo: Vol. 54 No. 3 (2002)
- I. Cavazzana, F. Bobbio-Pallavicini, C. Bazzani, E. Bravi, S. Zingarelli, A. Ceribelli, R. Caporali, R. Cattaneo, F. Franceschini, C. Montecucco, TNFa inhibition in anti-Ro/SSA positive patients with rheumatoid arthritis: clinical and immunological effects , Reumatismo: Vol. 58 No. 4 (2006)
- C. Botsios, P. Ostuni, S. Todesco, Incidence and management of infusion reactions to infliximab in 186 italian patient’s with rheumatoid arthritis: the Padua experience , Reumatismo: Vol. 57 No. 1 (2005)
- A. Hoxha, A. Ruffatti, P. Grypiotis, M. Podswiadek, C. Botsios, U. Fiocco, L. Punzi, S. Todesco, Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatement with infliximab , Reumatismo: Vol. 58 No. 2 (2006)
<< < 13 14 15 16 17 18 19 20 21 22 > >>
You may also start an advanced similarity search for this article.